UNLABELLED: Treatment of phenylketonuria involves a restriction in the intake of natural proteins. This can lead to growth impairment. Weight, height and body mass index of 109 hyperphenylalaninemic patients (mild hyperphenylalaninemia (HPA) and phenylketonuria (PKU)) were determined from birth until 18 years, every 6 months, and differences to the healthy population, depending on the age, sex and phenotype, were analyzed. Data collection was longitudinal retrospective during 31 years. Statistical analysis of z-score values was performed by advanced statistical tools. Long-term evolution of anthropometric z-scores showed no significant statistical differences between PKU and mild HPA individuals, according to the general population. For PKU individuals, height is slightly lower and weight slightly higher than in the healthy population, but differences are smaller than one standard deviation. Nevertheless, over-time evolutions of female height z-scores are different in each type of pathology, with a crossover between 8 and 12 years (p = 0.0186). CONCLUSIONS: It is nowadays possible to achieve a long-term normal growth in PKU patients with appropriate dietary treatment. There is however an acceleration of growth up to 8 years old for PKU female patients that leads to a slightly lower final height. Detection of this behaviour was possible by using nonlinear mixed effects models.
UNLABELLED: Treatment of phenylketonuria involves a restriction in the intake of natural proteins. This can lead to growth impairment. Weight, height and body mass index of 109 hyperphenylalaninemicpatients (mild hyperphenylalaninemia (HPA) and phenylketonuria (PKU)) were determined from birth until 18 years, every 6 months, and differences to the healthy population, depending on the age, sex and phenotype, were analyzed. Data collection was longitudinal retrospective during 31 years. Statistical analysis of z-score values was performed by advanced statistical tools. Long-term evolution of anthropometric z-scores showed no significant statistical differences between PKU and mild HPA individuals, according to the general population. For PKU individuals, height is slightly lower and weight slightly higher than in the healthy population, but differences are smaller than one standard deviation. Nevertheless, over-time evolutions of female height z-scores are different in each type of pathology, with a crossover between 8 and 12 years (p = 0.0186). CONCLUSIONS: It is nowadays possible to achieve a long-term normal growth in PKUpatients with appropriate dietary treatment. There is however an acceleration of growth up to 8 years old for PKU female patients that leads to a slightly lower final height. Detection of this behaviour was possible by using nonlinear mixed effects models.
Authors: M Hoeksma; M Van Rijn; P H Verkerk; A M Bosch; M F Mulder; J B C de Klerk; T J de Koning; E Rubio-Gozalbo; M de Vries; P J J Sauer; F J van Spronsen Journal: J Inherit Metab Dis Date: 2005 Impact factor: 4.982
Authors: Luis Aldámiz-Echevarría; María A Bueno; María L Couce; Sergio Lage; Jaime Dalmau; Isidro Vitoria; Fernando Andrade; Javier Blasco; Carlos Alcalde; David Gil; María C García; Domingo González-Lamuño; Mónica Ruiz; Luis Peña-Quintana; María A Ruiz; David González; Felix Sánchez-Valverde Journal: Clin Nutr Date: 2013-09-26 Impact factor: 7.324
Authors: A Carrascosa; J M Fernández; C Fernández; A Ferrández; J P López-Siguero; E Sánchez; B Sobradillo; D Yeste Journal: Endocrinol Nutr Date: 2009-01-07
Authors: P A Boepple; M J Mansfield; M E Wierman; C R Rudlin; H H Bode; J F Crigler; J D Crawford; W F Crowley Journal: Endocr Rev Date: 1986-02 Impact factor: 19.871
Authors: María-José de Castro; Paula Sánchez-Pintos; Nisreem Abdelaziz-Salem; Rosaura Leis; María L Couce Journal: Nutrients Date: 2021-06-20 Impact factor: 5.717